ISRCTN83324925 https://doi.org/10.1186/ISRCTN83324925

A Randomised Comparative Trial of Infusional ECF versus Conventional FEC as Adjuvant Chemotherapy in Patients with Poor Prognosis Breast Cancer

Submission date
19/08/2002

Recruitment status
No longer recruiting

Registration date
19/08/2002

Overall study status
Completed

Last Edited
03/12/2012

Condition category
Cancer

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof I Smith

Contact details
Royal Marsden Hospital
Downs Road
Sutton
Surrey
United Kingdom
SM2 5PT

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

ICR/TRAFIC

Study information

Scientific Title

Acronym
TRAFIC

Study objectives
To compare the relapse-free survival and survival of adjuvant infusional ECF with conventional FEC chemotherapy in patients <50 with node-positive early breast cancer.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at registration time

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Breast Cancer

Interventions
1. Infusional ECF Regimen: Chemotherapy, infusional ECF (epirubicin, cyclophosphamide, 5-fluorouracil)
2. FEC Regimen: Chemotherapy, conventional FEC (epirubicin, cyclophosphamide, 5-fluorouracil)

Intervention Type
Drug

Phase
Phase III

Drug/device/biological/vaccine name(s)
Infusional ECF versus Conventional FEC

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
26/06/1995

Completion date
30/01/2002

Eligibility

Key inclusion criteria
1. Confirmed invasive carcinoma of the breast
2. Treatment to start within 3 months of surgery
3. World Health Organisation (WHO) performance status of zero or one
4. Patients assessed as being competent to learn to look after Infumed or Graseby pump
5. No evidence of metastatic disease (routine Chest X-RAY [CXR], biochemistry)
6. Adequate haematological function
7. A glomerular filtration rate of greater than or equal to 60mls/minute. This can be measured by using an EDTA clearance or 24 hour urinary creatinine clearance at the investigators discretion
8. No other serious uncontrolled medical condition
9. No other malignancy, except carcinoma in situ of the cervix of basal cell carcinoma of the skin
10. Histologically proven invasive breast cancer (excision specimen or Trucut biopsy)
11. Upper age limit 50 years
12. Histologically involved axillary nodes
13. Written informed consent
14. Other investigations, e.g. bone scan, liver ultrasound, are only required for symptoms and/or abnormal biochemistry

Participant type(s)
Patient

Age group
Adult

Sex
Female

Target number of participants
Added 14/07/08: 348 patients

Key exclusion criteria
1. Any patient with a medicinal or psychiatric condition that impairs their ability to cope physically or psychologically with this chemotherapy regimen, or to give informed consent

2. Uncontrolled angina pectoris, heart failure, clinically significant uncontrolled or cardiac arrhythmias
3. Any other serious uncontrolled medical condition
4. Any pregnant or lactating woman
5. Other malignancy (excluding carcinoma in situ of cervix)

Date of first enrolment
26/06/1995

Date of final enrolment
30/01/2002

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Royal Marsden Hospital
Surrey
United Kingdom
SM2 5PT

Sponsor information

Organisation
Institute of Cancer Research (ICR) (UK)

Sponsor details
123 Old Brompton Road
London
United Kingdom
SW7 3RP

Sponsor type
Research organisation

Website
http://www.icr.ac.uk

ROR
https://ror.org/043jzw605

Funder(s)

Funder type
Research organisation

Funder Name
Institute of Cancer Research (ICR) (UK)

Alternative Name(s)
Institute of Cancer Research - CIHR, CIHR Institute of Cancer Research, L'Institut du cancer, Institut du cancer, ICR - CIHR, ICR, IC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
Canada

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2010		Yes	No